


(R)-JNJ-31020028

Cat. No.:	HY-107479
CAS No.:	1094873-17-2
Molecular Formula:	C ₃₄ H ₃₆ FN ₅ O ₂
Molecular Weight:	565.68
Target:	Neuropeptide Y Receptor
Pathway:	GPCR/G Protein; Neuronal Signaling
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	(R)-JNJ-31020028 is a high affinity, selective brain penetrant neuropeptide Y ₂ receptor antagonist, with pIC ₅₀ values of 8.07, 8.22 and 8.21 for human, rat, and mouse Y ₂ receptor, respectively. (R)-JNJ-31020028 shows >100-fold selective versus human Y ₁ , Y ₄ , and Y ₅ receptors. (R)-JNJ-31020028 has antidepressant like effects ^{[1][2]} .																		
IC₅₀ & Target	human Y ₂ receptor 8.07 (pIC ₅₀)	rat Y ₂ receptor 8.22 (pIC ₅₀)	mouse Y ₂ receptor 8.21 (pIC ₅₀)																
In Vivo	<p>(R)-JNJ-31020028 (5.6 µg; chronic icv infusion; daily for 10 days) has antidepressant like effects in the olfactory bulbectomized rat (OBX) model^[1].</p> <p>Chronic icv administration of (R)-JNJ-31020028 at 5.6 µg/day using osmotic Alzet pump resulted in a significant decreases number of grooming events^[1].</p> <p>(R)-JNJ-31020028 treatment shows the C_{max}, T_{max}, AUC_{inf}, V_d, and t_{1/2} were 4.35 µM, 0.5 hours, 7.91 h µM and 0.83 hours, respectively^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%;">Animal Model:</td> <td>Male Sprague Dawley rats weighing 150-170 (OBX model)^[1]</td> </tr> <tr> <td>Dosage:</td> <td>5.6 µg</td> </tr> <tr> <td>Administration:</td> <td>chronic icv infusion; daily for 10 days</td> </tr> <tr> <td>Result:</td> <td>Reduced OBX rat immobility time.</td> </tr> </table> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%;">Animal Model:</td> <td>male Sprague-Dawley rat^[2]</td> </tr> <tr> <td>Dosage:</td> <td>10 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>s.c. (Pharmacokinetic Analysis)</td> </tr> <tr> <td>Result:</td> <td>The C_{max}, T_{max}, AUC_{inf}, V_d, and t_{1/2} were 4.35 µM, 0.5 hours, 7.91 h µM and 0.83 hours, respectively.</td> </tr> </table>			Animal Model:	Male Sprague Dawley rats weighing 150-170 (OBX model) ^[1]	Dosage:	5.6 µg	Administration:	chronic icv infusion; daily for 10 days	Result:	Reduced OBX rat immobility time.	Animal Model:	male Sprague-Dawley rat ^[2]	Dosage:	10 mg/kg	Administration:	s.c. (Pharmacokinetic Analysis)	Result:	The C _{max} , T _{max} , AUC _{inf} , V _d , and t _{1/2} were 4.35 µM, 0.5 hours, 7.91 h µM and 0.83 hours, respectively.
Animal Model:	Male Sprague Dawley rats weighing 150-170 (OBX model) ^[1]																		
Dosage:	5.6 µg																		
Administration:	chronic icv infusion; daily for 10 days																		
Result:	Reduced OBX rat immobility time.																		
Animal Model:	male Sprague-Dawley rat ^[2]																		
Dosage:	10 mg/kg																		
Administration:	s.c. (Pharmacokinetic Analysis)																		
Result:	The C _{max} , T _{max} , AUC _{inf} , V _d , and t _{1/2} were 4.35 µM, 0.5 hours, 7.91 h µM and 0.83 hours, respectively.																		

REFERENCES

- [1]. Shoblock JR, et al. In vitro and in vivo characterization of JNJ-31020028 (N-(4-{4-[2-(diethylamino)-2-oxo-1-phenylethyl]piperazin-1-yl}-3-fluorophenyl)-2-pyridin-3-yl)benzamide), a selective brain penetrant small molecule antagonist of the neuropeptide YY(2) receptor. *Psychopharmacology (Berl)*. 2010 Feb;208(2):265-77.
- [2]. Morales-Medina JC, et al. Chronic administration of the Y2 receptor antagonist, JNJ-31020028, induced anti-depressant like-behaviors in olfactory bulbectomized rat. *Neuropeptides*. 2012 Dec;46(6):329-34.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA